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Purpose: A fully heterogeneous population averaged mechanistic tumor control probability (TCP)
model is appropriate for the analysis of external beam radiotherapy (EBRT). This has been accom-
plished for EBRT photon treatment of intermediate-risk prostate cancer. Extending the TCP model
for low and high-risk patients would be beneficial in terms of overall decision making. Furthermore,
different radiation treatment modalities such as protons and carbon-ions are becoming increasingly
available. Consequently, there is a need for a complete TCP model.
Methods: A TCP model was fitted and validated to a primary endpoint of 5-year biological
no evidence of disease clinical outcome data obtained from a review of the literature for low,
intermediate, and high-risk prostate cancer patients (5218 patients fitted, 1088 patients validated),
treated by photons, protons, or carbon-ions. The review followed the preferred reporting item for
systematic reviews and meta-analyses statement. Treatment regimens include standard fractionation
and hypofractionation treatments. Residual analysis and goodness of fit statistics were applied.
Results: The TCP model achieves a good level of fit overall, linear regression results in a p-value
of <0.000 01 with an adjusted-weighted-R2 value of 0.77 and a weighted root mean squared error
(wRMSE) of 1.2%, to the fitted clinical outcome data. Validation of the model utilizing three
independent datasets obtained from the literature resulted in an adjusted-weighted-R2 value of 0.78
and a wRMSE of less than 1.8%, to the validation clinical outcome data. The weighted mean absolute
residual across the entire dataset is found to be 5.4%.
Conclusions: This TCP model fitted and validated to clinical outcome data, appears to be an appro-
priate model for the inclusion of all clinical prostate cancer risk categories, and allows evaluation of
current EBRT modalities with regard to tumor control prediction. C 2016 American Association of
Physicists in Medicine. [http://dx.doi.org/10.1118/1.4939260]
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1. INTRODUCTION
Prostate cancer has the second highest incident rate and is
the fifth most mortal cancer in men.1 The highest incidence
rates are in Western and Northern Europe as well as Northern
America, principally due to prostate specific antigen (PSA)
testing and subsequent biopsy (Gleason score) being more
widespread. In widely screened populations such as Northern
America, the high-risk cohort represents only 15% of patients,
and a higher percentage will occur in less heavily screened
populations because screening identifies earlier presymp-
tomatic stages of the condition.2 External beam radiation
therapy (EBRT) is one of the primary treatment options to
treat prostate cancer.3 Advances in technology have led to
the development of three physically and potentially different
EBRT treatment modalities, viz., photon (X-EBRT), proton
(P-EBRT), and carbon-ion (C-EBRT) therapy.
Previous radiobiological modeling studies, both theoretical
and fitting exercises, have focused on X-EBRT (Refs. 4–15)
(of which a full and detailed review is deemed beyond
the scope of this work), an exception to this is a fitting
study16 where a tumor control probability (TCP) model17
was fit to data from lung cancer patients treated by C-EBRT
(Refs. 18–20) and a theoretical study exploring the upper and
lower bounds of the probability of cure in the context of C-
EBRT.21 However, to our knowledge, no TCP model has been
fit to prostate cancer outcome data treated by either P-EBRT
or C-EBRT. This work presents a TCP model22 applicable to
all EBRT modalities treating low, intermediate, and high-risk
T I. Clinical outcome dataset for fitting the TCP model.
Pats No. Modality d [Gy (E)] D [Gy (E)] 5-year bNED (%) ADT Risk References
362 X-EBRT 1.8 81.0 95 (PCC) Yesa Low-comb Kollmeier et al. (Ref. 27)
525 X-EBRT 1.8 81.0 89 (PCC) Yesa Int-comb Kollmeier et al. (Ref. 27)
412 X-EBRT 1.8 81.0 68 (PCC) Yesa High-comb Kollmeier et al. (Ref. 27)
111 X-EBRT/P-EBRT 1.8 70.2 83 (ASTRO) No Low-comb Zietman et al. (Ref. 29)
116 X-EBRT/P-EBRT 1.8 79.2 97 (ASTRO) No Low-comb Zietman et al. (Ref. 29)
68 X-EBRT/P-EBRT 1.8 70.2 75 (ASTRO) No Int-comb Zietman et al. (Ref. 29)
61 X-EBRT/P-EBRT 1.8 79.2 87 (ASTRO) No Int-comb Zietman et al. (Ref. 29)
606 P-EBRTb 2.0 74.0 84 (ASTRO) No Low-PSA Slater et al. (Ref. 25)
204 P-EBRTb 2.0 74.0 82 (ASTRO) No Low-Glea Slater et al. (Ref. 25)
339 P-EBRTb 2.0 74.0 65 (ASTRO) No Int-PSA Slater et al. (Ref. 25)
868 P-EBRTb 2.0 74.0 77 (ASTRO) No Int-Glea Slater et al.(Ref. 25)
133 P-EBRTb 2.0 74.0 48 (ASTRO) No High-PSA Slater et al. (Ref. 25)
86 P-EBRTb 2.0 74.0 50 (ASTRO) No High-Glea Slater et al. (Ref. 25)
89 P-EBRT 2.0 78.0 99 (PCC) Yesa Low-comb Mendenhall et al. (Ref. 23)
82 P-EBRT 2.0 80.0 99 (PCC) Yesa Int-comb Mendenhall et al. (Ref. 23)
40 P-EBRT 2.0 78.0 76 (PCC) Yes High-comb Mendenhall et al. (Ref. 23)
37 C-EBRT 3.3 66.0 100 (ASTRO) No Low-comb Tsuji et al. (Ref. 24)
164 C-EBRT 3.3 66.0 81 (ASTRO) Yes High-comb Tsuji et al. (Ref. 24)
33 C-EBRT 3.3 66.0 87 (PCC) No Low-comb Ishikawa et al. (Ref. 28)
142 C-EBRT 3.3 66.0 88 (PCC) Yes High-comb Ishikawa et al. (Ref. 28)
466 C-EBRT 3.3 66.0 90 (PCC) Yes Low/int/high-combc Okada et al. (Ref. 26)
274 C-EBRT 3.6 57.6 89 (PCC) Yes Low/int/high-combc Okada et al. (Ref. 26)
aA proportion of patients received ADT.
bA small proportion of patients also received X-EBRT.
cThe majority of patients were high-risk and were thus fit as a hybrid of intermediate and high-risk. Comb is defined as satisfying any dual combination of PSA, Gleason
score, or clinical staging to determine risk. bNED is defined by either the American Society for Therapeutic Radiology and Oncology (ASTRO—three consecutive PSA
rises post the PSA nadir) or the Phoenix Consensus Conference (PCC—2 ng/ml PSA rise above the PSA nadir) definition of biochemical failure.
prostate cancer patients and shows the capability of the model
to accurately predict TCP using biologically realistic input
parameters for radiosensitivity and clonogen density, as well
as clonogen density distribution and tumor hypoxia status
obtained from the fit presented below.
2. MATERIALS AND METHODS
2.A. The data used to fit the tumor control
probability model
The preferred reporting item for systematic reviews and
meta-analyses (PRISMA) checklist was utilized. A search
of the ScienceDirect database was performed in December
2014. Inclusion criterion was defined as papers that reported
the percentage success rate of 5-year biological no evidence
of disease (bNED—a surrogate for the probability of cure)
in relation to low, intermediate, or high-risk prostate cancer
patients treated by X-EBRT, P-EBRT, or C-EBRT. The use of
androgen deprivation therapy (ADT) was noted. The keyword
“prostate cancer” with subsearch criteria of “proton therapy”
or “carbon-ion” or “biochemical” or “bNED” was used. Seven
studies comprising 5218 patients treated between 1991 and
2009 were deemed eligible,23–28 see Table I. The quality of
evidence ranges from level-I (a properly designed randomized
controlled trial) to level-II (a well-designed cohort analytic
study) according to the United States preventive services
task force (www.uspreventiveservicestaskforce.org). Data are
available at doi:10.17195/candat.2015.10.8.
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2.B. The tumor control probability model
The TCP model uses the linear-quadratic (LQ) model of
radiation effect coupled with Poisson statistics,22 a modified
version of that originally proposed by Munro and Gilbert.30
The LQ model predicts the surviving fraction S(D) of a
population of cells exposed to a total uniform dose D,
where D is comprised of n fractions of uniform dose d.
The linear and quadratic coefficients of the LQ model are
α and β, respectively, describing inherent radiosensitivity.
Conventionally, α is linked with direct lethal damage and β
is linked with repairable sublethal damage,31
S(D)= exp−αnd− βnd2. (1)
The fully heterogeneous population averaged mechanistic
TCP model is obtained from Eq. (1) by assuming that α and β
are distributed normally and independently among prostatic
tumors within the patient population, characterized by the
average values ᾱ, β̄ and their standard deviations σα, σβ

















Here, N0 is the initial clonogen sum. TCP theory stems
from the postulation that control is only attained if zero
clonogens survive.32 Many studies have utilized the concept
of the dominant intraprostatic lesion (DIL) to define the
volume within the clinical target volume (CTV) most closely
associated with prostate cancer.33–38 This concept of clonogen
density distribution has been employed in this modeling study
via distinct clonogen density values, PCTV and PDIL, equal
to 105 cm−3 and 106 cm−3, respectively. The DIL volume is
assumed to be X% of the total CTV volume. The value for






An average volume for the CTV (prostate) of 36 cm3 was
used for low and intermediate-risk patients22 while an average
volume for the CTV (prostate and seminal vesicles) of 72 cm3
was used for high-risk patients,39 both of these values also
agree with local clinical measurements. Because the TCP
model presented in Eq. (2) is analytically intractable it is













Here, k signifies clusters of patients, each with a distinct
radiosensitivity. The modeling process is carried out compu-
tationally by selecting α and β from independent Gaussian
distributions; the values for α and β are used as inputs for
Eq. (4) and summed over the range, k. The precision of the
TCP model is determined by the size of k and was set to 5×105
for each Gaussian distribution, excluding negative values.
This ensures sufficient precision and convergence of the TCP
model. The effect of hypoxia on cell survival is substantial.40
Consequently, the patient population partial pressure of
oxygen (PO2) status was incorporated into the model through
two separate groups. Assuming that the distributions of DILs
and hypoxia are independent, the proportion of the total initial
number of clonogens defined as the hypoxic fraction and
the aerobic fraction in this modeling exercise was Y% and
100−Y%, respectively. This dependence on PO2 is described








The OER is dependent on the linear energy transfer (LET)
of radiation41 and must be modified when modeling C-EBRT.
2.C. Incorporating relative biological effectiveness
(RBE) into the tumor control probability model
Higher and lower LET radiations can be intercompared by
estimation of the RBE, defined as the ratio of lower and higher
LET doses required to produce a given biologic effect,42 such
as S(D) described by Eq. (1),
S(D)l = exp−αlndl− βlnd2l

, (6)







Conventionally, dose for ions is prescribed as Gy(E) by
scaling the physical dose by the RBE, for which clinical
values of 1.1 and 3.0 are used for P-EBRT and C-EBRT,
respectively.43 The studies included in our meta-analysis
followed this convention. However, RBE varies with LET,
dose, and radiosensitivity.44 Only some of these complex
biophysical interactions were included and purportedly ac-
counted for in the treatment planning of the studies included
in our meta-analysis. Therefore, a LQ-based RBE model44–46
which accounts for the dependence of RBE on LET, dose, and
radiosensitivity was employed to estimate RBEmin (asymptotic
value of RBE at dh =∞Gy) and RBEmax (asymptotic value of






















2.D. Fitting the tumor control probability model
Values obtained from a previous fit of this TCP model
to X-EBRT treatments of intermediate-risk patients22 were
utilized here as fixed values: α = 0.25 Gy−1, α/β = 2.48 Gy,
σα = 11.3%, σβ = 12.9%, DIL volume = 10%, hypoxic
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fraction = 15%, and OER = 1.75. This approach47 enables
fitting of the DIL volume and the hypoxic fraction for low
and high-risk prostate cancer patients as well as the RBEmin
and RBEmax of both P-EBRT and C-EBRT along with the
modification of the OER in the case of C-EBRT due to LET.
The TCP model is analytically intractable and consequently
standard fitting techniques are inappropriate, and the model
was therefore fitted using the Nelder–Mead (NM) simplex
algorithm48 (the same algorithm used in the previous fit of
this TCP model to X-EBRT treatments of intermediate-risk
patients22). The NM simplex algorithm is a robust method
for determining a local minimum of a function with several
variables.49,50 For nine variables—DIL volume (high and
low), hypoxic fraction (high and low), RBEmin (P-EBRT
and C-EBRT) and RBEmax (P-EBRT and C-EBRT), and the
modification of the OER in the case of C-EBRT due to LET—
a simplex is a decayotton and the technique is a pattern
search that equates function values at the ten vertices of the
simplex. The worst vertex is excluded and substituted with
a new vertex, and a new simplex is created and the search
continues. The algorithm transforms the simplex repetitively
based upon certain conditions until the termination test is
fulfilled. A single iteration of the NM method comprises the
following three steps.
1. Ordering: define the indices of the vertices from worst
to best, respectively, in the present operational simplex.
f (xn+1) > · ·· > f (x2) > f (x1) > f (x0) (i.e., xn+1 is the
worst vertex).
2. Centroid: compute the centroid x of the best face—the
one opposite the worst vertex, x = (1/n)i xi.
3. Transformation: calculate the new operational simplex
from the present one. Initially, attempt to substitute only
the worst vertex xn+1 with a superior vertex by means of
reflection, expansion, or contraction with respect to the
best face. If this succeeds, the superior vertex becomes
part of the new operational simplex. If this fails, the
entire simplex contracts toward the best vertex x0. In this
situation, n new vertices are computed. All test vertices
lie on the line defined by xn+1 and x. To minimize
the possibility that the algorithm could converge to a
suboptimal local solution instead of an optimum global
minimum, the algorithm began its pattern search for the
best possible solution with 2 359 296 initial guesses.
These starting points cover the known realistic range
of DIL volume, hypoxic fraction, RBEmin and RBEmax,
and the modification of the OER in the case of C-EBRT
due to LET.12,37,38,41,51–54 The algorithm was employed
to minimize the sum of the absolute residuals produced
by the TCP model, weighted to the number of patients
per data point.
2.E. Statistical evaluation of the goodness of fit
To quantify the accuracy of the TCP model, residuals,
defined as the difference between the specific clinical outcome
and the specific predicted TCP value, and linear regression
goodness of fit statistics, weighted to the number of patients
per data point to avoid bias, were used. The optimum
model fit is that which delivers the lowest weighted mean
absolute residual (wMAR), the lowest weighted root mean
squared error (wRMSE), and the highest adjusted-weighted-
R2 (coefficient of determination). These three statistical
metrics inhabit the same solution space due to weighting the
optimization process.
2.F. Validation of the tumor control probability model
To further evaluate and validate the TCP model, three
independent X-EBRT datasets comprising 27 data points and
consisting in total of 1088 low, intermediate, and high-risk
patients, acquired from the literature,55–57 were utilized. After
the fitting process was complete, the model was benchmarked
against these datasets. These datasets were previously used
to fit other TCP models and were thus deemed suitable for
validation, see the Appendix, Tables III and IV.
3. RESULTS
The optimized biological input parameters of the TCP
model obtained from the fit are listed in Table II. The
magnitude of the hypoxic fraction and the volume of the
DIL are both found to increase with risk group. The range
of variation in RBE is found to increase from P-EBRT to C-
EBRT. The OER of 1.75 for X-EBRT and P-EBRT is predicted
to be reduced by 14.4% [14.0%–19.6%] in the case of C-EBRT
due to high LET.
Linear regression of the model’s predictions, compared
to the fitted and validation clinical outcome datasets, is
displayed in Fig. 1 and resulted in an adjusted-weighted-
R2 value of 0.77–0.78 and a wRMSE of 1.2%–1.8%,
respectively. The model is highly significant with a p-value
of <1.0×10−6 in both the fitted and validation datasets. The
capability of the TCP model across multiple modalities, risk
groups, and fractionation regimes is compatible with a robust
radiobiological framework.
Figure 2 displays the residuals of the TCP model calculated
from both the fit and validation clinical outcome datasets. The
model is found to produce maximum and minimum residuals
of 44% and 0%, respectively. The major residuals correspond
to the data points associated with small patient numbers, and
T II. Optimization of the input parameters for the TCP model.
Risk group DIL volume (%) Hypoxic fraction (%)
Low 7.4a [3.5–8.9] 5.6a [5.2–6.8]
Intermediate 10.0b 15.0b
High 20.9a [10.3–21.5] 23.8a [23.3–34.4]
Treatment modality RBEmin RBEmax
X-EBRT N/A N/A
P-EBRT 1.0a [1.0–1.1] 1.2a [1.1–1.3]
C-EBRT 1.5a [1.4–1.8] 3.9a [3.7–5.3]
aThe value was obtained from the current fit of the TCP model.
bThe value was obtained from a previous fit of the TCP model.
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F. 1. Linear regression for the fit and validation of the TCP model: Each data point has a subscript indicating risk group (l : low, i: intermediate, and h:
high) and treatment modality (X : photon, P: proton, and C : carbon-ion). The circular area surrounding each data point has been scaled to reflect the number of
patients associated with that data point. The data express a high degree of correlation between the projected TCP outcomes and the reported clinical outcomes.
vice versa. The wMAR across the entire dataset is found to
be 5.4%.
The sensitivity of the biological solution space and
therefore fitted model parameters listed in Table II is
dependent upon the multiparametric construction of the TCP
model. Several permutations of DIL volume, hypoxic fraction,
RBEmin, RBEmax, and OER exist which provide a low wRMSE
(in combination with the fixed values for α, α/β, σα, and
σβ). This relationship is illustrated in Fig. 3, providing an
awareness of the possible permutations and range of the
biological solution space. Using the radiosensitivity values
employed here, the model always achieves a wRMSE of <3%
and adjusted-weighted-R2 > 0.3 for any permutation of DIL
volume, hypoxic fraction, RBEmin, RBEmax, and OER.
4. DISCUSSION
4.A. The accuracy and performance of the tumor
control probability model
The TCP model successfully predicts the 5-year bNED
clinical outcomes for X-EBRT, P-EBRT, and C-EBRT treat-
ments. The data express a high degree of correlation between
the predicted TCP outcomes and the reported bNED clinical
outcomes, providing a measure of confidence in the accuracy
of the TCP model across the various treatment modalities,
risk groups, and fractionation schemes. The lack of a distinct
pattern in the scatter of the residuals of the X-EBRT and P-
EBRT indicates a low likelihood of systematic error. However,
the TCP model does tend to overestimate the effectiveness of
C-EBRT; this is most likely due to both radiobiological and
geometrical matters, which are discussed further later.
The performance of the model as judged against the
validation datasets further strengthens the credibility of this
TCP model. However, a limitation of the validation dataset
is that only X-EBRT data were available as all the P-EBRT
and C-EBRT data were included in the model fit. Further
refinement and future validation of the model are required
once pertinent clinical outcome data mature.
4.B. Justification for the use of fixed
parameter values
The intrinsic radiosensitivity of prostate cancer is indepen-
dentofriskgroup.58Theradiosensitivityvalues(α = 0.25Gy−1,
α/β = 2.48 Gy, σα = 11.3%, σβ = 12.9%) used here were
Medical Physics, Vol. 43, No. 2, February 2016
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F. 2. Residuals for both the fitted and validation clinical outcome datasets: The right side of the fitted region corresponds to C-EBRT, the middle portion of
the fitted region corresponds to P-EBRT, and the left side of the fitted region as well at the entire validation region corresponds to X-EBRT. The graph displays
the residuals in terms of the absolute magnitude (white bars) and the weighted magnitude (colored bars for C-EBRT, P-EBRT, and X-EBRT, respectively). The
area of the bars is filled with the appropriate color to signify the relative weight of that data point, e.g., a data point representing 50% of the fitted region would
be 50% filled with color. The interpretation of this residual graph is best described as follows: Ideally, there would be no bars visible. If bars are visible they
ought not to contain color, indicating a low weight. The worst case scenario is that a large bar is visible and that it is full of color, indicating a high weight.
The weighted mean absolute residual across the entire dataset is found to be ±5.4% and is depicted by two dashed horizontal lines. The fitted region consists of
seven X-EBRT, P-EBRT, and C-EBRT datasets Refs. 23–28 comprising 22 data points containing a total of 5218 low, intermediate, and high-risk patients. The
validation region consists of three X-EBRT datasets Refs. 55–57 comprising 27 data points containing a total of 1088 low, intermediate, and high-risk patients.
The numbers above and below the bars indicate the number of patients associated with that data point.
obtained in a previous fit of this TCP model.22 These radio-
sensitivity values are in excellent agreement with both exper-
imental and clinical values reported in the literature through
meta-analysis.11,12 This approach47 enabled fitting of the DIL
volume and the hypoxic fraction for low and high-risk prostate
cancer patients, as well as RBEmin and RBEmax for P-EBRT
and C-EBRT, in addition to the modification of the OER in the
case of C-EBRT. The DIL volume and the hypoxic fraction for
intermediate-risk prostate cancer patients were known from the
previous fit of this TCP model22 for intermediate-risk patients
treated by X-EBRT.
4.C. The hypoxic fraction
Hypoxia in prostate cancer is associated with reduced
clinical tumor control.59,60 The estimated magnitude of the
hypoxic fraction listed in Table II is similar to values used in
the previous modeling studies.12,51 Experimental and clinical
evidence also supports the validity of this result. A survey of
all published data on hypoxic tumor fractions reported that
hypoxic fractions ranged from 0% to 50%, with a mean value
of 15%.53 This is similar to our mean hypoxic fraction of
14.6%, averaged across all risk groups.
4.D. The influence of the hypoxic fraction
Hypoxia is a key factor, together with radiosensitivity,
clonogen number, and dose, in determining TCP. Figure 4
shows the influence of hypoxia as a parameter on the
relationship between CTV/clonogen number and the predicted
TCP. A modest relationship is shown to exist between
the CTV/clonogen number and TCP. Conversely, the figure
evidently shows that the relationship between TCP and the
hypoxic fraction governs.
4.E. The oxygen enhancement ratio
In this study, we assume (as have others51,61) that the
OER value is consistent for both alpha and beta; however,
other studies have assumed and reported that the OER
varies.12,62 Furthermore, in this study, we also assume that
the OER remains constant for all the fractionation regimes63
for the low LET treatment modalities, X-EBRT and P-EBRT.
However, it is well known that for high LET radiation, the
OER is reduced.64 Typical dose mean LET values within
the target during C-EBRT treatment of the prostate are
50–60 keV/µm.39 Reduction of the OER effect through C-
EBRT LET was found to be 14.4%. This is in good agreement
with experimental in vitro results, where a reduction of 14%
has been reported in the OER for this change in LET.41 These
assumptions influence the model fit.
4.F. Dominant intraprostatic lesions
DILs are known to occur within the prostate and reoccur-
rence is typically located in these regions.12 The estimated
magnitude of the DIL volumes listed in Table II (12.3%
averaged across all risk groups) is comparable to values which
have been measured in clinical studies.37 Studies utilizing
imaging techniques, such as dynamic contrast enhanced
MRI and spectroscopic MRI, 11C-acetate and 111In-capromab-
pendetide, and 18F-choline PET/CT, have reported the average
DIL volume across all risk groups to be approximately 9%
with a range of 1%–37%.33–38
Medical Physics, Vol. 43, No. 2, February 2016
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F. 3. Biological solution space: A surface plot of the biological solution space is shown here and can be interpreted as an uncertainty map. The optimal global
minimum solution or the smallest wRMSE (depicted here as white circles) is found at DIL volumes equal to 7.4% and 20.9% with hypoxic fractions equal
to 5.6% and 23.8% for the low and high-risk groups, respectively. The corresponding RBEmin and RBEmax values for both P-EBRT and C-EBRT are 1.0–1.2
and 1.5–3.9, respectively. The OER reduction for C-EBRT is found to be optimal at 14.4%. An inverse relationship between the hypoxic fraction and the DIL
volume for low and high-risk patients is shown in (B) and (C). (A) displays the reduction in the OER for C-EBRT treatments for both low and high-risk patients
(left and right circles, respectively). The discontinuity is indicative of the boundary between low and high-risk patients. The OER was optimized simultaneously
in both risk groups, hence producing a single solution for both risk groups. (D) shows that the range of RBEmin and RBEmax values for P-EBRT is bounded
to approximately 1.0–1.2 while (E) shows a much greater range of RBEmin and RBEmax values for C-EBRT, permutations between 1.0–2.5 and 3.0–6.0 are
depicted. This is due to the narrow 5-year bNED range of the C-EBRT dataset (81%–100%) in contrast to the 5-year bNED characteristics of the P-EBRT
dataset (48%–100%).
4.G. The clinical significance of clongenic density,
distribution, and number
Accurate estimations of the density of clonogens in human
tumors12 fall in the range of 105−107 cm−3. Using these values
for clonogen density in combination with the assumption that
clonogens are homogeneously distributed throughout the CTV
is a flawed approach and leads to an inflated estimate of the to-
tal initial clonogen number and of radiosensitivity.22 Advanced
imaging techniques and histological analysis of radical prosta-
tectomy specimens have demonstrated that clonogen density is
not homogeneous.33–36,65 Frequently a single large DIL within
the prostate is present. This has led to the development of
dose painting approaches66–69 and consequently TCP models
that require this feature.70,71 Other TCP models that do not
account for this feature (whilst perfectly appropriate for the
prediction of uniform doses) are intrinsically lacking in the
context of dose and/or LET painting scenarios,72,73 which will
likely become more prevalent in the future. It should be noted
that the assumption of clongenic densities (PCTV and PDIL)
influences the model fit and that the model fit cannot determine
the distribution of clongenic densities.
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F. 4. Variation of TCP with CTV/clonogen number and hypoxic fraction: The variation of TCP with tumor volume and hypoxic fraction is shown. TCP
was calculated for X-EBRT total dose of 78 Gy delivered in 39 fractions using the biological input parameters α = 0.25 Gy−1, α/β = 2.48 Gy, σα = 11.3%,
σβ = 12.9%, DIL volume = 10%, and OER = 1.75. The light gray regions show the typical clinical range for CTV/clonogen number and hypoxic fraction. The
dark gray region displays the overlap of these variables.
4.H. Proliferation in prostate cancer
Proliferation has been shown to be of importance in radio-
therapy;74 nevertheless, it is not included in the TCP model as
prostate cancer is typically a slowly proliferating cancer with
a protracted delay before the commencement of regrowth.75,76
A recent analysis77 resulted in best estimates for proliferation
values of delay of onset before rapid proliferation, T(k)= 34
±7 days, and proliferative doubling time, T(d)= 12±2 days.
These values have limited influence on standard fractionation
and little or no effect on hypofractionation; however, in the
setting of low dose rate brachytherapy, these values would
have a major influence. The absence of proliferation is
defensible for two reasons. First is that the model did not
require a proliferation term to improve the fit of the model to
the clinical outcome data. Second is the Akaike information
criterion which evaluates the goodness of fit.78 This metric
penalizes models with unnecessary parameters which do
not contribute to the overall fit, therefore discouraging the
inclusions of nonessential parameters.
4.I. Application of the TCP model to other cancers
This TCP model can be applied to other solid cancer types,
provided that sufficient clinical outcome data are available to
fit the model. Previously published values for radiosensitivity,
clonogen density, and distribution coupled with hypoxia status
enable comparison/benchmarking for the model fit values and
strengthen the biological integrity of the model. Other clinical
sites (e.g., lung and head and neck) may need to incorporate
proliferation and the potential interplay effect with hypoxia,61
something which was not required for this prostate cancer
study. However, it should be noted that there are implications
for the Poissonian TCP approach implemented here in the
context of very rapidly proliferating tumors.5 It has been
demonstrated that the Poissonian TCP approach accurately
describes the probability of tumor cure when no proliferation
occurs during treatment; however, it underestimates cure when
very rapid proliferation occurs, delay of onset before rapid
proliferation, T(k)= 0 days, and proliferative doubling time,
T(d)= 2 days. But even in this extreme context, the inaccuracy
is not likely to exceed 10% and after most standard treatment
regimens it would often be much less than that.5
4.J. Hormonal therapy
ADT does not affect radiosensitivity.58 The X-EBRT and
C-EBRT datasets24,26–28 included ADT in all or a proportion
of the treated patients. The use of ADT can potentially be a
confounding factor and has been reported to improve bNED
outcome by approximately 5% for all risk groups. However, it
has also been reported that there is only a significant difference
in the bNED rate for high-risk groups and is dependent on the
period of ADT administration.79 Due to the lack of specific
information with regard to ADT administration and conflicting
reporting of efficacy in different risk groups, no explicit effort
was made within this modeling study to correct for the impact
from the use of ADT.
4.K. Risk group stratification
The exact definition of risk is controversial. Typical best
practice for risk classification incorporates three stratification
criteria: PSA level, Gleason histologic score, and tumor stage
to identify low, intermediate, and high-risk tumors. Definitions
to determine risk include any one of, or any dual combination
(comb) of, PSA, Gleason score, or clinical staging. Further-
more, the values of PSA, Gleason score, or clinical stage used
to stratify risk vary. The difference and overlap of definitions of
patient risk, asdepicted inFig.5, contribute to theoverall uncer-
tainty of modeling. There is a reasonable, but nonideal, degree
ofconsistencywithin thedatasetwith respect to riskgroupstrat-
ification. Overlap between risk groups exists in all three stratifi-
cation criteria. Improvements in the consistency of risk
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F. 5. Variation in risk group stratification: The image displays the disparity of exact definitions of risk. The ellipsoids represent patients classified in various
studies (see Table I) as low, intermediate, and high-risk, respectively, using the three stratification criteria of PSA, Gleason score, and clinical staging. Color
intensity reflects overlap. The lower cluster of ellipsoids correspond to low-risk stratification, the middle cluster of ellipsoids corresponds to intermediate-risk
stratification, and the upper cluster of ellipsoids corresponds to high-risk stratification.
stratification reporting would increase the analytical utility of
future data.
4.L. The definition of clinical outcomes
Evolution in clinical practice produces legacy issues for
modeling.80,81 In this study, bNED is defined by either the
American Society for Therapeutic Radiology and Oncology
(ASTRO—three consecutive PSA rises post the PSA nadir)
or the Phoenix Consensus Conference (PCC—2 ng/ml PSA
rise above the PSA nadir) definition of biochemical failure.82
Control rates defined by the ASTRO definition appear to
be worse at 2–5 yr, are convergent at 5–8 yr, and superior
at 8–12 yr in comparison with the PCC definition. The
sensitivity and specificity of the PCC definition is considered
to be more robust.82 This difference contributes to the overall
uncertainty of modeling. A primary endpoint of 5-year bNED
is utilized in this study. While utilization of both definitions
is nonideal, it can be justified for the following two reasons:
(1) A two-sample Kolmogorov–Smirnov test revealed that the
residuals from each definition are from the same continuous
distribution, i.e., the model does not significantly over or
underestimates bNED for either definition. (2) Strict adher-
ence to the current PCC definition would result in exclusion
of half the data listed in Table I (most notably in the P-EBRT
dataset, ∼92% is defined according to the ASTRO definition).
4.M. Dose heterogeneity
Dose heterogeneity can affect the results of TCP model-
ing,83,84 with underdosed areas being of special concern.32
X-EBRT of the prostate with conformal radiotherapy is
acknowledged as a robust treatment technique,85 delivering
a highly uniform dose to the target,86 consequently reducing
the possible influence of dose heterogeneity and cold spots
upon the TCP model. Subset analysis of X-EBRT resulted in
excellent correlation. Subset analysis of P-EBRT and C-EBRT
resulted in worse correlation, particularly in C-EBRT. The
well-defined range of ions enables precise dose localization
and highly conformal treatments. However, this property
renders ions sensitive to targeting uncertainties,87 relevant
for the prostate which undergoes considerable interfraction
displacements.88 Typical planning for C-EBRT completely
removes the posterior margin from the PTV in the latter half
of treatment.24,26,28 This possibly leads to cold spots in the
clinical target volume during C-EBRT treatment. The deliv-
ered dose and prescribed dose may, therefore, be different; this
could potentially explain the systematic overestimation of the
TCP model in predicting clinical outcome for C-EBRT.
4.N. Relative biological effectiveness
Clinical RBE values of 1.1 and 3.0 are used for P-EBRT
and C-EBRT, respectively.43 The studies included in our
meta-analysis followed this convention. However, the RBE
of ions varies with LET, dose, and radiosensitivity.44 The
RBE of P-EBRT and C-EBRT has been reported to vary
between 1.0–1.4 and 1.5–6.7, respectively.89 The estimated
values from this TCP model of RBEmin and RBEmax for P-
EBRT and C-EBRT listed in Table II are in agreement with
these previous findings. This variation in RBE potentially
has important ramifications for both dose/LET painting and
extreme fractionation regimens.
4.O. The limitations of the TCP model
The TCP model was fitted and validated to a primary
endpoint of 5-year bNED clinical outcome data. This has
two important consequences: the first is that the model is
constrained to a particular time point and the second is
that the model predicts population outcomes. In principle,
the model could predict both population outcomes and indi-
vidual outcomes, such as the Kattan-nomogram;90 however,
precise knowledge at the voxel level of each individual’s
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intratumor radiosensitivity, clonogenic density and clonogenic
distribution, hypoxia status, and RBE would be required to
be accurate. In order to overcome the temporal limitations
of this model, other mathematical approaches are required
such as the Zaider-survival-model.9 Finally, with regard to
the mathematical nature of the TCP model, it has been
demonstrated that the Poissonian TCP approach in the context
of very rapidly proliferating tumors5 has the potential to
underestimate cure (in this scenario the model would require
the incorporation of a repopulation term74). However, there
is also an additional associated concern that when fitting a
Poisson model to clinical outcome data from a homogeneous
population of rapidly proliferating tumors, the estimate of
total initial clonogen number N0 is biased downward (while
the resulting estimates of radiosensitivity and/or tumor growth
rate should still accurately reflect true values).5 In this study,
these concerns are offset by the fact that prostate cancer is a
heterogeneous population91 (accounted for in this mechanistic
TCP model through distribution of the radiosensitivity values)
of nonrapidly proliferating tumors75,76 (negating the need for
a repopulation term).
4.P. The TCP model qualitatively compared with other
empirical models
Preceding work has presented TCP models fitted to clinical
outcome data, such as those previously fitted to the validation
dataset55–57 utilized here. While they are appropriate for the
reproduction of the curve from which they were derived,
problems arise when extrapolating to situations that have some
changes compared to the reference conditions, i.e., fraction-
ation schemes. Empirical models such as the standard Poisson,
logistic, and Probit models, while useful for prediction in a
single fractionation domain space, offer limited insight into
the multiparametric complex causal physical and biological
processes present in EBRT treatment. Parametric information
with regard to intertumor radiosensitivity, clonogenic density
and clonogenic distribution, hypoxia status, and RBE is
all crudely encapsulated by D50 and γ values (i.e., these
quantities change when risk group, treatment modality, or
fractionation regimes change and are only applicable to uni-
form dose distributions). Mechanistic models are intrinsically
more powerful than empirical models as they parametrically
represent the fundamental processes driving patterns and are
more likely to work correctly when extrapolating beyond
the observed conditions, as was demonstrated with this TCP
model which extrapolated accurately to the stereotactic body
radiotherapy fractionation domain space.22 This is in stark
contrast to the empirical models previously fitted to the
validation dataset,55–57 which are constrained to conditions
of the fit (low, intermediate, and high-risk patients, treated by
X-EBRT with fractionation of 1.8–2.0 Gy). The TCP model
presented here has been fitted and validated in the context of
low, intermediate, and high-risk patients, treated by X-EBRT,
P-EBRT, and C-EBRT with fractionation of 1.8–3.6 Gy. These
are important facts with respect to this TCP model which
distinguishes it from other models.
4.Q. The merit of mechanistic models
A triumph of radiobiological research in radiation oncology
is the prediction of dose response. In contrast to empirical
models, mechanistic models accomplish this task with two
distinct advantages:6 (1) mechanistic models are much less
prone to overfitting and (2) their parameters characteristically
permit biophysical explanation, therefore maximizing the
value of such models as tools of scientific discovery. This
is the case with this TCP model as estimates of inter-
tumor radiosensitivity, clonogenic density and clonogenic
distribution, hypoxia status, and RBE are all provided.
Nevertheless, the TCP model presented here is also out of
necessity a simplification of the enormously complex reality
of the dynamics of irradiated tumors. Many other factors
that influence the response of tumors to irradiation such
as the delivered dose distribution, birth-and-death stochastic
processes, cell cycling, interaction with the immune system,
selection effects, spatial heterogeneity of the tumor, and its
capillary network, were not taken into account. These factors
will have all played a role to one degree or another in
determining outcomes and remain a challenge for the scientific
community to address and quantify through modeling.
5. CONCLUSION
A TCP model for prostate cancer has been demonstrated
to accurately forecast the 5-year bNED clinical outcomes in
both the fit and validation datasets, irrespective of treatment
modality, risk group, or fractionation scheme, using optimized
biological and radiosensitivity values. The values obtained
for the biological input parameters of the TCP model are in
good agreement with the previously reported values within
the literature. These biological values were obtained through
a fitting procedure, based upon clinical outcome data of 5218
prostate cancer patients. The results suggest that the model
presented is appropriate for the analysis and evaluation of
EBRT plans with regard to tumor control for a wide variety
of treatment techniques and clinical conditions. Finally, high-
level randomized evidence is yet to be provided for both P-
EBRT and C-EBRT. The mathematical construct of this TCP
model enables it to assist in future clinical trial design and
sample size determination.
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APPENDIX: SUPPLEMENTAL TABLES
The purpose of this appendix is to provide two tables which
summarize the TCP model parameters and the validation
dataset. Data is available at doi:10.17195/candat.2015.10.8.
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T III. Summary of the TCP model parameters.
Parameter Association Estimated from Input value
α Cancer type (prostate) Previous fit 0.25 Gy−1
β Cancer type (prostate) Previous fit 0.10 Gy−2
σα Cancer type (prostate) Previous fit 11.30%a
σβ Cancer type (prostate) Previous fit 12.90%a
RBEmax Modality (P-EBRT) Current fit 1.20
Modality (C-EBRT) Current fit 3.90
RBEmin Modality (P-EBRT) Current fit 1.00
Modality (C-EBRT) Current fit 1.50
OER Modality (X-EBRT/P-EBRT) Previous/current assumption 1.75
Modality (C-EBRT) Current fit 1.50
CTV Risk (low/intermediate) Current/previous assumption 36.00 cm3
Risk (high) Current assumption 72.00 cm3
DIL Risk (low) Current fit 7.40%b
Risk (intermediate) Previous assumption 10.00%b
Risk (high) Current fit 20.90%b
Hypoxic fraction Risk (low) Current fit 5.60%b
Risk (intermediate) Previous assumption 15.00%b
Risk (high) Current fit 23.80%b
aThe value is a percentage of the appropriate radiosensitivity characteristic α or β.
bThe value is a percentage of the appropriate CTV value low/intermediate or high.
T IV. Clinical outcome dataset for validating the TCP model.
Pats No. Modality d (Gy) D (Gy) 5-year bNED (%) ADT Risk References
7 X-EBRT 1.8 68.4 55 (ASTRO) No Low-comb Levegrün et al. (Ref. 57)
10 X-EBRT 1.8 72.8 77 (ASTRO) No Low-comb Levegrün et al. (Ref. 57)
16 X-EBRT 1.8 78.4 89 (ASTRO) No Low-comb Levegrün et al. (Ref. 57)
5 X-EBRT 1.8 66.6 20 (ASTRO) No Int-comb Levegrün et al. (Ref. 57)
9 X-EBRT 1.8 72.0 62 (ASTRO) No Int-comb Levegrün et al. (Ref. 57)
19 X-EBRT 1.8 77.4 20 (ASTRO) No Int-comb Levegrün et al. (Ref. 57)
13 X-EBRT 1.8 82.8 100 (ASTRO) No Int-comb Levegrün et al. (Ref. 57)
3 X-EBRT 1.8 66.6 0 (ASTRO) No High-comb Levegrün et al. (Ref. 57)
6 X-EBRT 1.8 72.0 29 (ASTRO) No High-comb Levegrün et al. (Ref. 57)
11 X-EBRT 1.8 77.4 44 (ASTRO) No High-comb Levegrün et al. (Ref. 57)
5 X-EBRT 1.8 82.8 100 (ASTRO) No High-comb Levegrün et al. (Ref. 57)
8 X-EBRT 2.0 60.0 82 (ASTRO) No Low-comb Cheung et al. (Ref. 56)
6 X-EBRT 2.0 62.0 62 (ASTRO) No Low-comb Cheung et al. (Ref. 56)
31 X-EBRT 2.0 64.0 63 (ASTRO) No Low-comb Cheung et al. (Ref. 56)
11 X-EBRT 2.0 66.0 57 (ASTRO) No Low-comb Cheung et al. (Ref. 56)
14 X-EBRT 2.0 68.0 78 (ASTRO) No Low-comb Cheung et al. (Ref. 56)
47 X-EBRT 2.0 70.0 77 (ASTRO) No Low-comb Cheung et al. (Ref. 56)
39 X-EBRT 2.0 78.0 92 (ASTRO) No Low-comb Cheung et al. (Ref. 56)
42 X-EBRT 2.0 64.0 38 (ASTRO) No Int-comb Cheung et al. (Ref. 56)
28 X-EBRT 2.0 66.0 32 (ASTRO) No Int-comb Cheung et al. (Ref. 56)
19 X-EBRT 2.0 68.0 57 (ASTRO) No Int-comb Cheung et al. (Ref. 56)
75 X-EBRT 2.0 70.0 62 (ASTRO) No Int-comb Cheung et al. (Ref. 56)
36 X-EBRT 2.0 78.0 74 (ASTRO) No Int-comb Cheung et al. (Ref. 56)
153 X-EBRT 2.0 66.0 25 (ASTRO) No High-comb Cheung et al. (Ref. 55)
103 X-EBRT 2.0 68.0 49 (ASTRO) No High-comb Cheung et al. (Ref. 55)
261 X-EBRT 2.0 70.0 38 (ASTRO) No High-comb Cheung et al. (Ref. 55)
111 X-EBRT 2.0 78.0 52 (ASTRO) No High-comb Cheung et al. (Ref. 55)
Note: Comb is defined as satisfying any dual combination of PSA, Gleason score, or clinical staging to determine risk. bNED is defined as the American Society for
Therapeutic Radiology and Oncology (ASTRO—three consecutive PSA rises post the PSA nadir).
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